-
Feb 05, 2021 08:57 PM IST Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 666 in its research report dated January 28, 2021.
-
Nov 06, 2020 04:39 PM IST Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 671 in its research report dated November 03, 2020.
- Aug 08, 2020 12:33 PM IST
Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 576 in its research report dated August 05, 2020.
- Jun 04, 2020 01:26 PM IST
Prabhudas Lilladher recommended accumulate rating on Eris Lifesciences with a target price of Rs 576 in its research report dated Jun 03, 2020.
- Nov 08, 2019 11:53 AM IST
Prabhudas Lilladher recommended accumulate rating on Eris Lifesciences with a target price of Rs 459 in its research report dated November 07, 2019.
- Jul 31, 2019 11:23 AM IST
Prabhudas Lilladher recommended accumulate rating on Eris Lifesciences with a target price of Rs 459 in its research report dated July 29, 2019.
- Jan 30, 2019 12:17 PM IST
Prabhudas Lilladher recommended accumulate rating on Eris Lifesciences with a target price of Rs 695 in its research report dated January 29, 2019.
- Nov 14, 2018 05:12 PM IST
Prabhudas Lilladher recommended accumulate rating on Eris Lifesciences with a target price of Rs 704 in its research report dated November 05, 2018.
- Jun 01, 2018 04:31 PM IST
Prabhudas Lilladher recommended accumulate rating on Eris Lifesciences with a target price of Rs 885 in its research report dated May 28, 2018.
- Oct 30, 2017 04:34 PM IST
Bonanza is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 686 in its research report dated October 26, 2017.
- Aug 24, 2017 03:11 PM IST
Axis Direct is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 730 in its research report dated 23 August 2017.
- Jun 16, 2017 10:01 AM IST
With a predominant focus on the domestic formulations market, a robust portfolio of largely prescription-based drugs, and a tilt towards a promising chronic portfolio, the company seems fundamentally strong.
